QuidelOrtho Corporation, a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2023 IMV ServiceTrak Awards for the sixth consecutive year. The […]
Hitesh
Astellas Completes Acquisition of Iveric Bio
Astellas Pharma Inc. announced that it has successfully completed the acquisition of IVERIC bio, Inc. with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has […]
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Gilead Science Inc, announced its largest commitment to health equity for Indigenous Australian and Canadian communities. This initiative will support programs to remove social barriers to care that continue to contribute to HIV and viral hepatitis transmission in Indigenous communities. Gilead is in talks with two Indigenous-led organizations, the Lowitja […]
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Genmab A/S today announced that the European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP) has adopted a positive opinion proposing a conditional marketing authorization for ecoritamab as monotherapy in the treatment of adult patients with relapsed or refractory dual- or multiple-lineage systemic B-cell lymphoma (DLBCL). The European Commission’s […]
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
Genentech, a member of the Roche Group, announced today that data from its ophthalmology portfolio will be featured in 25 abstracts at the American Society of Retina Specialists (ASRS) Annual Meeting (ASRS). ) 2023, taking place from July 28 to August 1 in Seattle, WA. The data reinforce the depth […]
Establishment Labs Celebrates Opening of Sulàyöm Innovation Campus and Outlines New and Expanded Capabilities
Establishment Labs Holdings Inc., a global health technology company dedicated to improving women’s health and well-being, primarily in breast aesthetics and reconstruction, today announced the opening of its facility at Sulayöm innovation in the Coyol Free Zone, Costa Rica. The Sulayöm campus will support the continued growth of Established Laboratories […]
Nutex health hospitals win six new outstanding awards
Nutex Health Inc., a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that six Nutex hospitals have won notable awards this quarter. Each award was voted on by their respective communities, as a reflection of […]
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Zolbetuximab
Astella Pharma Inc. announced that the European Medicines Agency (EMA) has accepted regulatory review of the company’s Marketing Authorization (MA) Application for zolbetuximab, an experimental first-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with locally advanced, unresectable or metastatic gastric or esophageal adenocarcinoma (GEJ) whose […]
KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer
KSQ Therapeutics, Inc., a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISRomics® discovery platform, today announced that it has entered into a worldwide licensing and partnership agreement with Roche to develop and commercialize the KSQ-4279. KSQ-4279 is a selective, potent, first-class small molecule inhibitor of USP1, a protein […]
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
Genentech, a member of the Roche Group , announced that the OCARINA II phase III trial evaluating Ocrevus® (ocrelizumab) as a 10-minute subcutaneous injection twice a year met the primary and secondary endpoints in patients with the Relapsing MS or primary progressive MS (RMS or PPMS). Subcutaneous Ocrevus was found […]
